The animal health supplement market has grown up without ever being given a clear legal home. That is the central problem the National Animal Supplement Council (NASC) is seeking to solve with the Animal Health Supplement Act.

Today, supplements for dogs, cats, horses, and specialty pets are widely sold and used, and increasingly expected by consumers and retailers. Yet unlike human dietary supplements, there is no clear federal statutory category that defines these products, explains how they should be regulated, specifies what claims they may make, outlines how ingredients should be evaluated, or sets the line between a supplement and a drug.

Instead, the market operates under a patchwork of enforcement discretion, state feed concepts, voluntary standards, and practical workarounds.

Subscribe to our newsletters to stay up to date with all our news and analysis.

That lack of clarity has real consequences. It creates uncertainty for manufacturers, confusion for consumers, friction for state regulators, and inefficiency for the FDA. It also rewards inconsistency. In a gray-market environment, the companies that try hardest to comply often bear the greatest burden, while less disciplined actors exploit ambiguity. That is not a recipe for consumer confidence or sound regulation.

The Animal Health Supplement Act is designed to replace that uncertainty with a framework that is more transparent, more predictable, and better suited to the products actually on the market.

A Real Market Operating in an Incomplete Framework

Animal supplements are not a theoretical category. They are already a significant part of the companion animal and equine marketplace. Products are sold to support mobility, skin and coat health, digestive health, calming, immune function, and general wellness. Consumers increasingly expect these products to be available, and retailers increasingly expect them to be part of the category mix. Veterinarians and pet professionals encounter them every day.

But the legal structure has lagged the market. The bill’s findings acknowledge that the FDA has historically exercised enforcement discretion over many of these products, even though they could otherwise be viewed as unapproved new animal drugs, depending on how the agency interprets intended use. That is precisely the problem. A mature market should not depend indefinitely on regulatory discretion rather than a defined statutory framework.

Why NASC’s Role Matters

One of the strongest arguments for the legislation is that the industry has already demonstrated what a more disciplined and transparent framework can look like.

For years, NASC has played a central role in bringing practical order to a category that still lacks a clear legal home. NASC has developed quality, labeling, and post-market surveillance standards that have helped responsible companies operate more consistently in a difficult, often fragmented regulatory environment.

The current draft bill expressly recognizes NASC’s role in the marketplace and highlights the significance of its Adverse Event Reporting System, which includes data on thousands of products and ingredients. It also directs the FDA to consult with NASC and other stakeholders during implementation.

That is important because NASC’s role has not been limited to trade advocacy. It has been functional. In an area where federal law has not yet provided a fully tailored framework, NASC has helped companies build one in practice. The bill reflects that reality. It does not start from a blank page; it builds on a system that industry has already demonstrated can work.

“NASC has helped bring discipline, transparency, and practical uniformity to a category that still lacks a clear statutory home,” said NASC President Bill Bookout.

What the Bill Would Do

The Animal Health Supplement Act would establish a statutory category for Animal Health Supplements and confirm that they are treated as food under the Act. That alone would be significant, but the draft goes much further than merely defining the category.

The bill establishes a framework for ingredient review, sets a framework for structure/function claims, provides for a product listing system, requires adverse event reporting, authorizes risk-based cGMP regulations tailored to the category, and includes strong preemption and enforcement provisions intended to reduce regulatory fragmentation and limit private litigation based on technical FDCA theories.

One of the most important elements is the bill’s preclusion framework. That provision is designed to address a recurring problem: the risk that products will be treated as unapproved drugs simply because an ingredient has been approved as a drug or is under public investigation as one.

The draft does not eliminate the distinction between supplements and drugs. Instead, it sets out rules for when preclusion should and should not apply. It ties the analysis to intended conditions of use, therapeutic effect, prior marketing, public investigation, active development, abandonment, and a petition process for non-precluded uses. This marks a major shift away from discretionary, case-by-case uncertainty and toward a more rules-based system.

Why Regulatory Certainty Helps Industry

For manufacturers and marketers, regulatory certainty is not merely a legal luxury. It is an operational necessity.

A defined framework helps companies make better decisions about formulation, ingredient sourcing, labeling, claims, post-market systems, and investment. It makes it easier to determine whether a product should be positioned as a supplement or a feed product, whether a particular claim is supportable, and what kind of ingredient support will be needed. It also makes it easier to scale products nationally when the rules are more uniform.

The bill would also help address one of the market’s quieter yet more important issues: the lack of a level playing field. In gray-market sectors, ambiguity often benefits the least disciplined actors. A more transparent, well-defined system rewards responsible companies that invest in quality, science, compliance, and surveillance.

Why Regulatory Certainty Helps Consumers

Consumers benefit when products are regulated under a framework that reflects their actual nature.

The bill would improve transparency by establishing a product listing system, promoting more standardized labeling, requiring appropriate disclosures, and strengthening post-market oversight. It would also provide a clearer legal basis for distinguishing between general wellness or structure/function support claims and disease-treatment claims. That distinction is essential. Consumers should be able to rely on a marketplace where supplement claims are understandable, drug claims remain prohibited unless appropriately approved, and products are not forced into the wrong category simply because the law has not kept pace with the market.

Why Regulatory Certainty Helps FDA

A clearer statute is also beneficial for the FDA. When an agency must govern an entire category through broad interpretations and informal discretion, it invites criticism from every direction.

A more tailored statutory framework gives the FDA clearer authority, clearer boundaries, better reporting systems, and a more administrable structure. The current draft also addresses one of the FDA’s practical concerns by including dedicated authorization of appropriations tied to staffing, IT systems, review timelines, and performance reporting.

In other words, the bill is not asking the FDA to do less. It is providing the agency with a better framework for doing its job.

Why Regulatory Certainty Helps States

State regulators remain central to how these products are treated in practice, particularly where feed concepts and AAFCO-influenced interpretations shape ingredient and labeling expectations. Yet that same reality also creates fragmentation. Different states may apply different assumptions to similar products, forcing companies to maintain multiple label versions, undergo duplicative review, or adopt inconsistent product positioning.

The bill’s preemption provisions are intended to reduce that fragmentation while preserving government enforcement authority. A clearer federal framework would not eliminate the states’ role. It would give them a better anchor.

The Bottom Line

The Animal Health Supplement Act is not about reducing oversight. It is about replacing uncertainty with a system.

It recognizes that the market already exists, that consumers already rely on these products, that responsible companies are already operating in a disciplined manner, and that NASC has already done substantial work to bring order to a category that federal law has never fully addressed. The bill would take those realities and provide a coherent statutory framework.

That would be good for industry because it would provide predictability. It would be good for consumers because it would improve transparency and accountability. It would be good for the FDA because it would replace discretion with clearer authority. And it would be good for state regulators because it would reduce unnecessary fragmentation.

The real question is no longer whether the animal health supplement market exists. It plainly does. The question is whether federal law is finally ready to provide it with a proper home.